When was Ladderbio founded?

Ladderbio was founded in 2020 and raised its 1st funding round 5 years after it was founded.

Where is Ladderbio located?

Ladderbio is headquartered in Blue Bell, United States.

Is Ladderbio a funded company?

Ladderbio is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Nov 12, 2025.

When was the latest funding round of Ladderbio?

Ladderbio's latest funding was a $***** Seed round on Nov 12, 2025, with participation from 2 investors. Its primary sector is Diversified Pharmaceuticals. In United States, the Diversified Pharmaceuticals sector has seen $20.4M in funding in 2026 to date.

Where does Ladderbio rank among its competitors?

Ladderbio ranks 239th amongst 1214 active competitors, of which 68 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Ladderbio, which secured $5.5M in Nov, 2025.

Who are the top competitors of Ladderbio?

Ladderbio's top competitors include Amgen, AbbVie and Gilead. Among them, Ladderbio secured the most recent funding round in November, 2025.

Ladderbio - 2026 Company Profile, Funding & Competitors

Ladderbio is a seed company based in Blue Bell (United States), founded in 2020. It operates as a Developer of sequence-defined, structurally preorganized molecules for challenging biological targets. Ladderbio has raised $5.5M in funding from Medical Excellence Capital. The company has 1214 active competitors, including 68 funded and 150 that have exited. Its top competitors include companies like Amgen, AbbVie and Gilead.

Company Details

Developer of sequence-defined, structurally preorganized molecules for challenging biological targets. The company designs peptide-like molecules intended to be orally available and cell permeable. It focuses on creating new treatment options where conventional modalities are insufficient. A venture capital firm invests in early-stage life sciences companies. The firm partners with teams to build businesses across therapeutics and precision medicine technologies.

Key Metrics

Founded Year

2020

Location

Blue Bell, United States

Stage

Seed

Total Funding

$5.5M in 1 round

Latest Funding Round

Seed, Nov 12, 2025, $*****

Investors

Medical Excellence Capital & 1 more

Ranked

239^th among 1214 active competitors

Similar Companies

Amgen & 1240 more

View Ladderbio's full profile

Ladderbio has raised a total funding of $5.5M over 1 round. Its latest funding round was a Seed round on Nov 12, 2025 for $*****. 2 investors participated in its latest round. Ladderbio has 2 institutional investors.

Here is the list of recent funding rounds of Ladderbio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 12, 2025	9278325	Seed	4104936	3576675	5401088	6784871

Access funding benchmarks and valuations. Sign up today!

View details of Ladderbio's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Ladderbio include Amgen, AbbVie and Gilead. Here is the list of Top 10 competitors of Ladderbio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Amgen 1980, Thousand Oaks (United States), Public	Developer of pharmaceutical products for treating multiple diseases	-	Amgen Business Development, Digital Pharma Lab ... & 11 others	83/100
2nd	AbbVie 2012, Chicago (United States), Public	Research-based biopharmaceutical company	$14.7B	Alcor Fund, Berkshire Hathaway & 8 others	81/100
3rd	Gilead 1987, Foster City (United States), Public	Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others	-	Aisling Capital, BB Biotech & 17 others	81/100
4th	Lilly 1876, Indianapolis (United States), Public	Developer of traditional pharmaceutical medicines	-	Alcor Fund, Digital Pharma Lab & 11 others	80/100
5th	Johnson & Johnson 1886, New Brunswick (United States), Public	Manufacturer and supplier of beauty care products, medical devices, and pharmaceutical products	-	Alcor Fund, 27th Street Capital & 16 others	78/100
6th	Pfizer 1849, New York City (United States), Public	Provider of pharmaceutical products for multiple disease treatments	-	Alcor Fund, Benson Family Private Equity ... & 16 others	77/100
7th	Juno Therapeutics 2013, Seattle (United States), Acquired	Global biopharmaceutical company discovering, developing, and delivering innovative medicines	$317M	RA Capital Management, BB Biotech & 14 others	74/100
8th	Roivant Sciences 2014, New York City (United States), Public	Developer of therapeutics to treat neurology, oncology, rare, and endocrinology based diseases	$1.3B	SoftBank Vision Fund, NovaQuest Capital Management ... & 7 others	71/100
9th	Novartis 1996, Basel (Switzerland), Public	R&D focused on manufacturing of drugs for multiple therapeutic areas	-	Digital Pharma Lab, MT Capital & 9 others	70/100
10th	Roche 1896, Basel (Switzerland), Public	Developer of pharmaceuticals and diagnostics kits	-	SoftBank Group, Capricorn Partners & 10 others	70/100
239th	Ladderbio 2020, Blue Bell (United States), Seed	Developer of sequence-defined, structurally preorganized molecules for challenging biological targets	$5.5M	Medical Excellence Capital, Hatch BioFund	30/100